How methyl‑adding enzymes like SMYD3 help aggressive childhood medulloblastoma

Role of Methyltransferases in MYC-driven Medulloblastoma

NIH-funded research St. Jude Children's Research Hospital · NIH-11178022

This project looks at whether blocking a methyltransferase called SMYD3 can slow aggressive, MYC-driven medulloblastoma in children.

Quick facts

Grant typeP01 program project
Study typeNIH-funded research
Funding institutionSt. Jude Children's Research Hospital NIH-funded
Lab location1 site (Memphis, United States)
Project IDNIH-11178022 on NIH RePORTER

What this research studies

Researchers will focus on Group 3 medulloblastoma tumors that have high MYC levels and look for non-mutated epigenetic drivers like SMYD3. They will use lab-grown human tumor cells, mouse models, and analyses of human tumor samples to see how SMYD3 affects tumor growth and MYC expression. Mass spectrometry and chromatin assays (like ATAC‑seq and methylation profiling) will be used to find proteins and DNA regions that SMYD3 interacts with. If blocking SMYD3 reduces tumor growth in preclinical models, it could guide new targeted therapies for these high‑risk tumors.

Who could benefit from this research

Good fit: Children (most often ages 3–7) with Group 3 medulloblastoma that show MYC overexpression would be the most relevant candidates for related trials or sample donations.

Not a fit: Patients with medulloblastoma subtypes that are not driven by MYC, or with other brain tumor types, are unlikely to benefit from SMYD3‑targeted approaches.

Why it matters

Potential benefit: If successful, this work could identify a new drug target that leads to more effective, less toxic treatments for children with MYC‑driven medulloblastoma.

How similar studies have performed: Other epigenetic‑targeting strategies have shown promise in lab models, but targeting SMYD3 in MYC‑driven medulloblastoma is a relatively new, largely preclinical approach.

Where this research is happening

Memphis, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions Brain Cancer
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.